Bioxel Turns to Yew in Production of Cancer Drugs for You with New $15 Million Plant in Quebec

---

Researched by Industrialinfo.com (Industrial Information Resources, Incorporated; Houston, Texas). Bioxel Pharma (Sainte-Foy, Quebec) is set to start construction on a new pharmaceutical manufacturing plant in La Pocatiere, Quebec (PEC 60001318). The company's focal point is the development and production of taxanes, which are used in the treatment of cancer, Alzheimer's disease and multiple sclerosis. Taxanes are derived from the Canadian Yew tree, which is abundant in the Bas-Saint-Laurent region, which was major factor in deciding where to build the plant.

Bioxel Pharma has put together a series of exclusive Canadian yew harvesting rights, comprised of both public and private forestlands they total over 56,000 square miles. The company employs a sustainable development approach in its harvesting practices in order to ensure the preservation and regeneration of the Canadian yew. Under sustainable yield conditions, Bioxel Pharma's available harvest represents the potential for an annual taxanes production capacity of over 5,000 kilograms.

Click the following link to view Industrialinfo.com's new 2004 North American Pharmaceutical-Biotech Forecast.